Search

everythinglearnresearchcommunity

for

Search:↓

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

Adding a second method to PROTACs could improve cancer treatment.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

MK-5108 is safe and shows potential against tumors, especially alone.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Vinblastine can help treat childhood ITP but may cause reversible side effects.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

Intravenous arsenic is safe and effective for treating certain blood cancers.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

The treatment was effective and tolerable for advanced gastric cancer.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

A woman with severe angioedema improved significantly after treatment with rituximab.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Tocilizumab might be an effective treatment for COVID-19.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.